Combination treatment for advanced liver cancer
Part of Cancer clinical trials.
This trial tests a combination of two immunotherapy drugs, TACE (a procedure to block blood flow to tumors), and lenvatinib (a targeted therapy) for people with liver cancer that has not responded to initial treatment. It aims to see if this combination can help shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with hepatocellular carcinoma (a type of liver cancer) that cannot be removed with surgery.
- You have already tried a first treatment that included a PD-1/PD-L1 inhibitor plus bevacizumab, and it did not work or you could not tolerate it.
- You are 18 years or older.
- Your liver function is good enough (Child-Pugh class A or B, score 7 or less) and you do not have a history of hepatic encephalopathy (a condition where the liver can't remove toxins from the blood, affecting the brain).
- You have at least one tumor that can be measured on a scan.
- You have not had any bleeding from veins in your esophagus or stomach in the last 6 months, and an endoscopy within the last 3 months shows no high-risk varices (enlarged veins).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of treatments—chemotherapy given directly into the liver, two immunotherapy drugs, and a targeted therapy—for people with liver cancer that is too large or complex for immediate surgery. The goal is to shrink the tumor enough to make surgery possible later.
This trial compares two standard treatments (TACE and HAIC) when combined with an immunotherapy drug (PD-1 inhibitor) and an oral targeted therapy (lenvatinib) for people with liver cancer that cannot be surgically removed. The goal is to see which approach works better in shrinking tumors and improving outcomes.
This trial tests whether adding a liver-directed treatment to standard systemic therapy can improve outcomes for people with liver cancer that cannot be removed. It may help shrink tumors or slow the disease while on current treatment.
This trial tests a combination of immunotherapy drugs, radiation therapy, and a targeted therapy drug before and after surgery for people with intermediate-stage liver cancer that can be surgically removed. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination treatment for advanced liver cancer that cannot be removed with surgery. It combines a procedure (irreversible electroporation) that uses electrical pulses to destroy cancer cells, with targeted therapy (lenvatinib) and immunotherapy (sintilimab) to help your immune system fight the cancer.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus lenvatinib (a targeted therapy) given before surgery for hepatocellular carcinoma (a type of liver cancer). The goal is to see if this treatment can shrink tumors and reduce the chance of cancer coming back after surgery.
Hear when a new HCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.